Tag: Prescription Drugs

Absence of moderate or severe headache reported in 46 and 29 percent of prodrome events that had been treated with ubrogepant, placebo

One of five trials in the FDA review was positive; all three trials in the published literature were positive

Guidelines include strong recommendations for monoclonal antibodies and JAK inhibitors

Two trials show lower amyloid plaque burden with gantenerumab versus placebo at 116 weeks

Reduction seen in risk for developing composite kidney outcome

Overall survival benefit demonstrated among patients with metastatic breast cancer who had received trastuzumab and taxanes

Greater incidence of grade 3 or higher adverse events from any cause seen in combination group versus monotherapy

Improvement in overall survival seen for patients receiving cisplatin or carboplatin with pemetrexed

Both visceral adipose percentage and infliximab levels independently tied to steroid-free deep remission

Decreases seen at week 12, with most of the decrease achieved at two and four weeks after cessation of combined hormonal contraceptives